TABLE 3.
Peripheral Blood Biomarkers in Patients with CIP
| Nonrefractory CIP N=44 | Refractory CIP N=16 | P | |
|---|---|---|---|
| At baseline | |||
| WBC, median (IQR) | 7.36 (6.02, 10.35) | 8.18 (6.25, 11.1) | 0.772 |
| ANC, median (IQR) | 5.09 (3.85, 7.34) | 5.68 (3.66, 8.35) | 0.676 |
| ALC, median (IQR) | 1.46 (0.97, 1.9) | 1.29 (1.07, 1.73) | 0.831 |
| AEC, median (IQR) | 0.17 (0.11, 0.32) | 0.1 (0.06, 0.21) | 0.154 |
| NLR, median (IQR) | 3.93 (2.41, 5.91) | 3.47 (2.71, 7.84) | 1.000 |
| PLR, median (IQR) | 190.3 (111.08, 305.81) | 207.29 (149.63, 441.2) | 0.504 |
| LDH, median (IQR) | 216 (183, 252) | 255 (222, 418) | 0.031 |
| At CIP | |||
| WBC, median (IQR) | 8.21 (5.85, 11.41) | 8.38 (6.24, 9.09) | 0.635 |
| ANC, median (IQR) | 5.76 (3.37, 8.63) | 6.12 (3.86, 7.65) | 0.765 |
| ALC, median (IQR) | 1.16 (0.81, 1.66) | 0.98 (0.62, 1.63) | 0.580 |
| AEC, median (IQR) | 0.11 (0.04, 0.27) | 0.12 (0.04, 0.2) | 0.835 |
| NLR, median (IQR) | 4.71 (2.55, 10.81) | 4.5 (3.12, 9.3) | 0.993 |
| PLR, median (IQR) | 218.57 (155.5, 397.83) | 262.07 (192.34, 376.04) | 0.456 |
| LDH, median (IQR) | 219 (198, 241) | 321.5 (216.75, 487.5) | 0.019 |
| Changes from baseline to CIP development | |||
| WBC, median (IQR) | 0.45±3.38 | −0.55±3.51 | 0.335 |
| ANC, median (IQR) | 0.57±3.53 | -0.16±2.97 | 0.480 |
| ALC, median (IQR) | −0.23 (-0.54, 0.08) | −0.22 (−0.4, 0) | 0.890 |
| AEC, median (IQR) | −0.04 (−0.14, 0.11) | 0.03 (−0.08, 0.14) | 0.493 |
| LDH, median (IQR) | 7 (−24.5, 44) | 66 (0, 165) | 0.042 |
Statistically significant P and corresponding biomarker values are in bold.
AEC indicates absolute eosinophil count; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CIP, checkpoint inhibitor-related pneumonitis; LDH, lactate dehydrogenase, the unit for LDH is U/L; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; WBC, white blood cell count.